ZC84.1 Antibody

What is ZC84.1 and what cellular functions does it regulate in C. elegans?

ZC84.1 is a protein encoded in Caenorhabditis elegans that is identified by the UniProt accession number Q03610 . While specific functions are not fully characterized in the available literature, C. elegans proteins are widely studied for their roles in developmental biology, neuroscience, and aging research. The antibody targeting this protein serves as a valuable tool for detecting and studying its expression patterns, localization, and potential functional roles in cellular processes.

What validation assays confirm ZC84.1 antibody specificity?

For C. elegans antibodies like ZC84.1, specificity validation typically involves multiple complementary approaches:

• Western blotting to confirm detection of a single band at the expected molecular weight

• Immunoprecipitation to verify antibody-antigen interaction

• RNAi knockdown or genetic mutants as negative controls

• Cross-reactivity testing against related proteins

When selecting any research antibody, validation documentation showing these specificity tests should be reviewed carefully, similar to the validation protocols described for antibodies like CD84 .

What are the recommended applications for ZC84.1 antibody?

Based on similar C. elegans antibody products in the catalog, ZC84.1 antibody is likely applicable for:

These applications would be consistent with standard research protocols used with similar antibodies like those listed in the catalog .

How should I optimize ZC84.1 antibody for Western blotting in C. elegans samples?

For optimal Western blot results with ZC84.1 antibody:

• Sample preparation: Homogenize worms in ice-cold lysis buffer containing protease inhibitors.

• Protein loading: Load 20-40 μg of total protein per lane.

• Blocking optimization: Test both 5% non-fat milk and 3-5% BSA in TBST, as C. elegans proteins may respond differently.

• Antibody dilution: Begin with 1:1000 dilution and adjust based on signal strength.

• Incubation conditions: Incubate primary antibody overnight at 4°C with gentle agitation.

• Controls: Include wild-type and known genetic mutants when possible to validate specificity.

This approach mirrors validated protocols for other model organism antibodies that require careful optimization .

What fixation and permeabilization methods are recommended for immunostaining C. elegans with ZC84.1 antibody?

For immunofluorescence applications with C. elegans-targeting antibodies:

• Fixation options:

  • Paraformaldehyde (4%) fixation for 10-30 minutes preserves most epitopes while maintaining tissue architecture

  • Methanol fixation (-20°C) for 5 minutes may be preferable for certain subcellular structures

• Permeabilization:

  • 0.1-0.5% Triton X-100 for 5-15 minutes after fixation

  • For challenging epitopes, consider 1% SDS treatment for 10 minutes

• Blocking:

  • 1-5% BSA with 0.1% Tween-20 in PBS for 30-60 minutes

Similar to protocols used for antibodies like ZNF384, optimization of fixation conditions is critical for maintaining both tissue morphology and epitope accessibility .

How can I quantify ZC84.1 protein expression levels across different developmental stages?

To accurately quantify expression across C. elegans developmental stages:

• Synchronize worm populations using standard hypochlorite treatment.

• Collect samples at key developmental timepoints (embryo, L1-L4, young adult, aging adult).

• Extract proteins using consistent methodology for all samples.

• Perform Western blotting with ZC84.1 antibody alongside loading controls (actin, tubulin).

• Use at least three biological replicates per developmental stage.

• Quantify band intensity using image analysis software.

• Normalize target protein levels to loading controls.

• Apply statistical analysis to determine significant differences between stages.

This developmental profiling approach provides valuable insights into expression patterns that may correlate with specific biological processes.

How can ZC84.1 antibody be used in co-immunoprecipitation to identify novel protein interactions?

For discovering ZC84.1 protein interaction networks:

• Cross-linking protocol:

  • Treat live worms with 1% formaldehyde for 10 minutes to stabilize protein-protein interactions

  • Quench with 125 mM glycine

• Co-IP procedure:

  • Prepare lysates in non-denaturing buffer with protease inhibitors

  • Pre-clear lysate with Protein A/G beads

  • Incubate cleared lysate with ZC84.1 antibody (5-10 μg) overnight at 4°C

  • Add fresh beads, incubate 2-4 hours

  • Perform stringent washing (at least 5×)

  • Elute complexes and analyze by mass spectrometry

• Controls:

  • IgG control to identify non-specific binding

  • Reverse IP with antibodies to suspected interacting partners

  • Validation using mutant strains

This approach parallels successful techniques used to identify interaction networks for antibodies like those described in the immune checkpoint studies .

What strategies can overcome epitope masking when ZC84.1 is in protein complexes?

Epitope masking is a common challenge when proteins form complexes or undergo conformational changes. Advanced strategies include:

• Epitope retrieval methods:

  • Heat-mediated retrieval (95-100°C for 5-20 minutes in appropriate buffer)

  • pH-based methods (citrate buffer pH 6.0 or Tris-EDTA pH 9.0)

  • Enzymatic digestion with proteinase K (1-5 μg/ml for 5-15 minutes)

• Denaturing approaches:

  • SDS treatment (0.1-1%) followed by thorough washing

  • Urea treatment (2-8M) with step-down renaturation

• Alternative fixation protocols:

  • Sequential fixation with different agents

  • Reduced fixation time with careful optimization

These techniques can significantly improve detection of masked epitopes, similar to approaches used in therapeutic antibody research .

How can I use ZC84.1 antibody for chromatin immunoprecipitation to identify DNA binding sites?

For ChIP applications with ZC84.1 antibody:

• Cross-linking protocol:

  • Treat synchronized worm populations with 1% formaldehyde for 10 minutes

  • Quench with 125 mM glycine

• Chromatin preparation:

  • Lyse samples and sonicate to achieve fragments of 200-500 bp

  • Verify fragmentation by agarose gel electrophoresis

• Immunoprecipitation:

  • Pre-clear chromatin with protein A/G beads

  • Incubate with 5-10 μg ZC84.1 antibody overnight at 4°C

  • Add fresh beads, incubate 2-4 hours

  • Wash with increasingly stringent buffers

• Analysis options:

  • ChIP-qPCR for known target regions

  • ChIP-seq for genome-wide binding site identification

• Controls:

  • Input chromatin (non-immunoprecipitated)

  • IgG negative control

  • Positive control using antibody to known DNA-binding protein

This methodology parallels advanced ChIP protocols used in other model organisms and can reveal important regulatory functions.

What are common causes of high background when using ZC84.1 antibody in immunofluorescence?

High background in C. elegans immunofluorescence can stem from several factors:

Similar troubleshooting approaches have been effective with antibodies like those described for ICC/IF applications .

How can I resolve conflicting results between ZC84.1 antibody detection and mRNA expression data?

Protein-mRNA discrepancies are common in research and require systematic investigation:

• Validation of antibody specificity:

  • Confirm with multiple detection methods (Western blot, IP, IF)

  • Use knockout/knockdown controls

• Post-transcriptional regulation assessment:

  • Measure protein half-life using cycloheximide chase

  • Investigate microRNA targeting using prediction tools and reporter assays

• Translational efficiency analysis:

  • Polysome profiling to assess translation rates

  • Ribosome footprinting for detailed translational regulation

• Protein localization:

  • Subcellular fractionation may reveal compartmentalization affecting detection

  • Detergent solubility testing for aggregation or complex formation

This methodological approach aligns with strategies used to resolve similar discrepancies in antibody-based research .

What strategies can improve ZC84.1 antibody detection of low-abundance proteins?

For enhanced detection of low-abundance targets:

• Sample enrichment:

  • Subcellular fractionation to concentrate target compartments

  • Immunoprecipitation followed by Western blotting

  • Tissue-specific extraction from transgenic animals expressing cell-specific markers

• Signal amplification:

  • Tyramide signal amplification (TSA) for immunofluorescence (10-100× signal enhancement)

  • Enhanced chemiluminescence (ECL) substrates with extended incubation

  • Biotin-streptavidin amplification systems

• Instrument optimization:

  • Extended exposure times with low-noise detection systems

  • Spectral unmixing to separate target signal from background

  • Super-resolution microscopy for detailed localization

• Protocol modifications:

  • Extended primary antibody incubation (overnight to 48 hours at 4°C)

  • Reduced washing stringency (lower salt concentration)

  • Signal enhancers in blocking buffer (PVA, PVP)

These approaches have successfully enhanced detection in challenging samples across various model systems .

How does ZC84.1 antibody performance compare to antibodies targeting orthologous proteins in other model organisms?

When comparing antibody performance across species:

Cross-species applications require rigorous validation with appropriate positive and negative controls, similar to the approach used in therapeutic antibody development .

What are the considerations for using ZC84.1 antibody in multiplexed imaging applications?

For multiplexed imaging with ZC84.1 antibody:

• Antibody compatibility assessment:

  • Host species combinations to avoid cross-reactivity

  • Isotype selection for secondary antibody discrimination

  • Epitope availability in fixed samples

• Fluorophore selection criteria:

  • Spectral separation to minimize bleed-through

  • Photobleaching resistance for sequential imaging

  • Quantum yield for balanced signal intensity

• Protocol optimization:

  • Sequential antibody application with blocking steps

  • Careful order of antibody application (rare targets first)

  • Stripping and reprobing validation

• Controls:

  • Single-color controls for spillover correction

  • Secondary-only controls for background assessment

  • Competition assays to confirm specificity

These considerations align with established practices in advanced immunofluorescence applications and facilitate multi-target analysis in complex samples .

How can ZC84.1 antibody be used in proximity ligation assays to study protein-protein interactions in situ?

For in situ proximity ligation assays (PLA) with ZC84.1 antibody:

• Experimental design:

  • Pair ZC84.1 antibody with antibody against suspected interaction partner

  • Ensure antibodies are from different host species

  • Optimize individual antibody concentrations before combination

• Protocol considerations:

  • Fixation optimization to preserve both protein epitopes

  • PLA probe selection compatible with both primary antibodies

  • Rolling circle amplification time calibration

• Controls required:

  • Omission of one primary antibody

  • Known interacting proteins as positive control

  • Non-interacting protein pairs as negative control

  • RNAi knockdown of target protein

• Analysis approaches:

  • Quantification of PLA puncta per cell/region

  • Co-localization with subcellular markers

  • Developmental or condition-dependent changes in interaction

This advanced application provides powerful insights into protein interactions with spatial resolution, similar to techniques used in developing therapeutic antibodies for immune checkpoint interactions .